Adjunct Associate Professor
Wyeth Genetics Institute
87 Cambridge Park Drive
Cambridge, MA 02140
Phone: 617-665-8784
FAX: 617-665-8880
Email: uschwert@mediaone.net

Research Interests:

Dr. Schwertschlag is a Senior Director of Experimental Medicine, Cambridge MA, Wyeth-Ayerst Research/Genetics Institute (WAR-GI). His research at WAR-GI includes clinical studies in the areas of inflammation, immunology, and clinical pharmacology of protein drugs and small molecules.

Recent Publications:

Berl, T. and Schwertschlag, U.S.: Preclinical and Pharmacologic Basis for Clinical Use of rhIL-11 as an Effective Platelet-Support Agent (2000). Oncology, Supplement 8:12-20

Schwertschlag, U.S.: Mechanism and Amelioration of Recombinant Human Iterleukin-11 Induced Anemia in Healthy Subjects (2001): Thrombocytopenia in Oncology, Vol.1 No.1:5-7.

Oestreicher, J.L., Walters I.B., Kikuchi T., Gileaudeau, P., Surette, J., Schwertschlag, U., Dorner, A., Krueger J.G. and Trepicchio W.L.: Pharmacogenomic expression profiling identifies psoriasis genes (2201) The Pharmacogenomics Journal. In press.

Monette M. Cotreau, Lucille Sonis, Kevin H. Dykstra, Thimma Gandhi, Maria Gutierrez, Jing Xu, Young Park, Peter Burghart, Ulrich S. Schwertschlag: Multiple dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. (2001) J. Clin Pharm. In press.